| scholarly article | Q13442814 |
| P2093 | author name string | Madhavi Reddy | |
| Daryl Ramai | |||
| Smruti Mohanty | |||
| Vahe Shahnazarian | |||
| P2860 | cites work | NS5B polymerase inhibitors in phase II clinical trials for HCV infection | Q47260158 |
| Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era. | Q47274505 | ||
| Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial | Q50104601 | ||
| Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. | Q50532119 | ||
| Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. | Q50564292 | ||
| A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on | Q85608080 | ||
| EASL Recommendations on Treatment of Hepatitis C 2016 | Q88412279 | ||
| Hepatitis C and insulin action: An intimate relationship | Q26775000 | ||
| Chronic hepatitis C virus infection and lipoprotein metabolism | Q26784234 | ||
| Review article: HCV genotype 3 – the new treatment challenge | Q26864571 | ||
| Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 | ||
| The natural history of hepatitis C virus (HCV) infection | Q27473116 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options | Q29620126 | ||
| Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
| The global burden of hepatitis C | Q29620138 | ||
| Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death | Q30151690 | ||
| Hepatitis C genotype 3 disease. | Q30244065 | ||
| Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis | Q30251862 | ||
| The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry | Q30689293 | ||
| Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. | Q31040495 | ||
| Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? | Q33731308 | ||
| Protective immunity against hepatitis C: many shades of gray. | Q33759224 | ||
| Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource | Q33777199 | ||
| Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more | Q34172595 | ||
| Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. | Q34294185 | ||
| Global distribution and prevalence of hepatitis C virus genotypes | Q34431175 | ||
| Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. | Q34467208 | ||
| The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 | Q34533596 | ||
| Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study | Q34626591 | ||
| Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial | Q34649453 | ||
| Epidemiology of hepatitis C virus in HIV-infected patients. | Q34672079 | ||
| An overview of HCV molecular biology, replication and immune responses | Q34916120 | ||
| Side effects of therapy of hepatitis C and their management | Q34984142 | ||
| HCV and HIV co-infection: mechanisms and management. | Q35090634 | ||
| The history of the "natural history" of hepatitis C (1968-2009). | Q35216592 | ||
| Treatment of hepatitis C: a systematic review | Q35223637 | ||
| All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study | Q35538245 | ||
| Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States | Q35619161 | ||
| Sequence diversity of hepatitis C virus: implications for immune control and therapy | Q36179696 | ||
| Hepatitis C virus infection: Are there still specific problems with genotype 3? | Q36269670 | ||
| HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. | Q36399139 | ||
| Pathogenesis of accelerated fibrosis in HIV/HCV co-infection | Q36727294 | ||
| Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease | Q37015738 | ||
| Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV | Q37252421 | ||
| Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). | Q37349005 | ||
| Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs | Q37619741 | ||
| Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. | Q37699395 | ||
| Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis | Q37944951 | ||
| Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies | Q37972774 | ||
| Evolving epidemiology of hepatitis C virus in the United States | Q38020157 | ||
| New horizons in hepatitis C antiviral therapy with direct-acting antivirals. | Q38087250 | ||
| Current progress in development of hepatitis C virus vaccines. | Q38120201 | ||
| New antiviral agents for the treatment of hepatitis C: ABT-450. | Q38187167 | ||
| New hepatitis C therapies: the toolbox, strategies, and challenges | Q38196150 | ||
| Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'. | Q38249236 | ||
| Hepatitis C virus RNA replication and assembly: living on the fat of the land | Q38294573 | ||
| The mechanism of HCV entry into host cells | Q38321419 | ||
| Hepatitis C virus therapeutic development: in pursuit of "perfectovir". | Q38374284 | ||
| High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis | Q38389634 | ||
| Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis | Q38572687 | ||
| Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study. | Q38657409 | ||
| Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions | Q38728564 | ||
| Genotype 3 Infection: The Last Stand of Hepatitis C Virus | Q38772047 | ||
| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study | Q38839762 | ||
| Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review | Q38893244 | ||
| Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation | Q38961331 | ||
| Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis | Q39007128 | ||
| Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. | Q39008634 | ||
| Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. | Q39151731 | ||
| Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial | Q39259481 | ||
| Designing an HCV vaccine: a unique convergence of prevention and therapy? | Q39333862 | ||
| HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma | Q40050150 | ||
| Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). | Q40073712 | ||
| Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CRE | Q40085056 | ||
| Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? | Q40092669 | ||
| The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms | Q40140184 | ||
| Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study | Q40262011 | ||
| Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs | Q40522620 | ||
| Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. | Q40671938 | ||
| The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? | Q40736300 | ||
| No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered? | Q40831555 | ||
| Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection | Q40907444 | ||
| Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. | Q41066364 | ||
| Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. | Q41109284 | ||
| Cost-effectiveness of novel regimens for the treatment of hepatitis C virus | Q41211125 | ||
| Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection | Q41729517 | ||
| Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis | Q41929750 | ||
| Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial | Q41934673 | ||
| Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. | Q42225921 | ||
| Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study | Q42226115 | ||
| Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. | Q42243136 | ||
| Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner | Q42977580 | ||
| Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity | Q43031928 | ||
| IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. | Q43035545 | ||
| Meta-analysis: insulin resistance and sustained virological response in hepatitis C. | Q43037279 | ||
| Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. | Q43039596 | ||
| HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis | Q43040452 | ||
| Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients | Q43041131 | ||
| Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. | Q43041821 | ||
| Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection | Q45707657 | ||
| Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy | Q46572193 | ||
| Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. | Q46719182 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 541-551 | |
| P1433 | published in | Annals of Gastroenterology | Q15758811 |
| P1476 | title | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges | |
| P478 | volume | 31 |
Search more.